Hologic (NASDAQ:HOLX) versus Its Peers Critical Comparison

Hologic (NASDAQ: HOLX) is one of 87 publicly-traded companies in the “Advanced Medical Equipment & Technology” industry, but how does it contrast to its competitors? We will compare Hologic to related companies based on the strength of its dividends, earnings, risk, valuation, analyst recommendations, profitability and institutional ownership.

Valuation and Earnings

This table compares Hologic and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Hologic $3.06 billion $330.80 million 14.76
Hologic Competitors $2.13 billion $221.25 million -29.10

Hologic has higher revenue and earnings than its competitors. Hologic is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of recent recommendations for Hologic and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hologic 0 4 9 0 2.69
Hologic Competitors 271 1875 3367 108 2.59

Hologic currently has a consensus target price of $47.54, indicating a potential upside of 21.99%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 7.40%. Given Hologic’s stronger consensus rating and higher possible upside, equities analysts plainly believe Hologic is more favorable than its competitors.


This table compares Hologic and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Hologic 24.70% 21.69% 7.20%
Hologic Competitors -299.27% -35.18% -12.46%

Insider & Institutional Ownership

96.0% of Hologic shares are held by institutional investors. Comparatively, 51.0% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 0.8% of Hologic shares are held by insiders. Comparatively, 18.7% of shares of all “Advanced Medical Equipment & Technology” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk & Volatility

Hologic has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500. Comparatively, Hologic’s competitors have a beta of 1.52, indicating that their average stock price is 52% more volatile than the S&P 500.


Hologic beats its competitors on 10 of the 13 factors compared.

Hologic Company Profile

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays. It offers viral load assays for the quantitation of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus-1 (HIV-1). The Breast Health products include breast imaging and related products and accessories, including digital mammography systems, computer-aided detection (CAD) and breast biopsy guidance systems. The GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers and mini C-arm imaging systems.

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply